CN113166087B - 屏蔽剂及其用途 - Google Patents
屏蔽剂及其用途 Download PDFInfo
- Publication number
- CN113166087B CN113166087B CN201980076992.7A CN201980076992A CN113166087B CN 113166087 B CN113166087 B CN 113166087B CN 201980076992 A CN201980076992 A CN 201980076992A CN 113166087 B CN113166087 B CN 113166087B
- Authority
- CN
- China
- Prior art keywords
- cancer
- imaging
- compound
- effective amount
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862734690P | 2018-09-21 | 2018-09-21 | |
| US62/734690 | 2018-09-21 | ||
| PCT/US2019/051903 WO2020061293A1 (en) | 2018-09-21 | 2019-09-19 | Shielding agents and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113166087A CN113166087A (zh) | 2021-07-23 |
| CN113166087B true CN113166087B (zh) | 2024-05-10 |
Family
ID=69887812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980076992.7A Active CN113166087B (zh) | 2018-09-21 | 2019-09-19 | 屏蔽剂及其用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210323985A1 (https=) |
| EP (1) | EP3853213A4 (https=) |
| JP (2) | JP7429688B2 (https=) |
| CN (1) | CN113166087B (https=) |
| WO (1) | WO2020061293A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015011118B1 (pt) * | 2012-11-15 | 2022-12-13 | Endocyte, Inc | Conjugado; composição farmacêutica; e uso de um conjugado |
| BR112016010927A2 (pt) | 2013-11-14 | 2017-08-08 | Endocyte Inc | Conjugado de fórmula |
| US12208102B2 (en) | 2018-04-17 | 2025-01-28 | Endocyte, Inc. | Methods of treating cancer |
| CN114096264B (zh) | 2019-05-20 | 2025-03-14 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| CA3237590A1 (en) * | 2021-11-09 | 2023-05-08 | James Basilion | Psma targeted conjugate compounds and uses thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101778910A (zh) * | 2006-11-08 | 2010-07-14 | 分子制药洞察公司 | 谷氨酸的异质二聚体 |
| CN103930432A (zh) * | 2011-06-15 | 2014-07-16 | 癌靶技术有限责任公司 | 螯合的psma抑制剂 |
| WO2015055318A1 (en) * | 2013-10-18 | 2015-04-23 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| CN111801121A (zh) * | 2017-04-11 | 2020-10-20 | 约翰霍普金斯大学 | 在psma靶向癌症成像或放疗期间用于健康组织保护的2-pmpa前药 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4464384A3 (en) | 2007-08-17 | 2025-01-08 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| BR112015011118B1 (pt) * | 2012-11-15 | 2022-12-13 | Endocyte, Inc | Conjugado; composição farmacêutica; e uso de um conjugado |
| US9988407B2 (en) | 2014-08-06 | 2018-06-05 | The Johns Hopkins University | Prodrugs of prostate specific membrane antigen (PSMA) inhibitor |
| AU2015315465B2 (en) | 2014-09-08 | 2019-08-29 | Molecular Insight Pharmaceuticals, Inc. | Organ protection in PSMA-targeted radionuclide therapy of prostate cancer |
-
2019
- 2019-09-19 EP EP19863710.0A patent/EP3853213A4/en active Pending
- 2019-09-19 CN CN201980076992.7A patent/CN113166087B/zh active Active
- 2019-09-19 JP JP2021515616A patent/JP7429688B2/ja active Active
- 2019-09-19 WO PCT/US2019/051903 patent/WO2020061293A1/en not_active Ceased
- 2019-09-19 US US17/277,806 patent/US20210323985A1/en active Pending
-
2023
- 2023-12-04 JP JP2023204832A patent/JP7748438B2/ja active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101778910A (zh) * | 2006-11-08 | 2010-07-14 | 分子制药洞察公司 | 谷氨酸的异质二聚体 |
| CN103930432A (zh) * | 2011-06-15 | 2014-07-16 | 癌靶技术有限责任公司 | 螯合的psma抑制剂 |
| WO2015055318A1 (en) * | 2013-10-18 | 2015-04-23 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| CN111801121A (zh) * | 2017-04-11 | 2020-10-20 | 约翰霍普金斯大学 | 在psma靶向癌症成像或放疗期间用于健康组织保护的2-pmpa前药 |
Non-Patent Citations (1)
| Title |
|---|
| 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for Pet Imaging;Eder, M; 等人;《Bioconjugate Chemistry》;第23卷(第4期);688-697 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022501383A (ja) | 2022-01-06 |
| JP7429688B2 (ja) | 2024-02-08 |
| EP3853213A1 (en) | 2021-07-28 |
| EP3853213A4 (en) | 2022-07-06 |
| US20210323985A1 (en) | 2021-10-21 |
| JP2024028840A (ja) | 2024-03-05 |
| JP7748438B2 (ja) | 2025-10-02 |
| WO2020061293A1 (en) | 2020-03-26 |
| CN113166087A (zh) | 2021-07-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113166087B (zh) | 屏蔽剂及其用途 | |
| KR102902487B1 (ko) | 에반스 블루 유도체의 화학적 접합체 및 전립선 암 표적화를 위한 방사선 치료 및 조영제로서의 용도 | |
| ES2960030T3 (es) | Tratamiento de células cancerosas que sobreexpresan receptores de somatostatina utilizando derivados de ocreótido quelados con radioisótopos | |
| JP7840115B2 (ja) | 癌を治療する方法 | |
| AU2019345320B2 (en) | Methods of treating cancer | |
| CN101626787A (zh) | 诊断的和治疗的环氧合酶-2结合配体 | |
| CN116217505B (zh) | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 | |
| JP2025503451A (ja) | 炭酸脱水酵素ixリガンド | |
| CN121909051A (zh) | 靶向成纤维细胞活化蛋白的组合物及其使用方法 | |
| WO2026039503A1 (en) | Fibroblast activation protein-targeted compositions and methods of use thereof | |
| HK40047004A (en) | Methods of treating cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |